PhaseBio Pharmaceuticals Gross Profit

As of the most recent data (June 2022), PHAS shows a gross profit of $820K. That compares with $11M in the prior-year period — down 92.3% year over year. That is below the Healthcare sector average of $64B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PHAS's gross profit is now $820K (was $11M) — a 92.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PhaseBio Pharmaceuticals is outperforming or lagging.

The Healthcare sector average gross profit is about $64B. PhaseBio Pharmaceuticals is at $820K, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how PHAS stacks up against individual peers as well.

Tracking PHAS's gross profit over time shows whether PhaseBio Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $820K That compares with $11M in the prior-year period — down 92.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has PhaseBio Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $820K) with ownership activity and broader fundamentals.